Skip to Content

'
Ernest Hawk, MD, MPH

Present Title & Affiliation

Primary Appointment

Vice President, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Division Head, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Department Chair ad interim, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Department Chair ad interim, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Ernest T. Hawk, MD, MPH, is vice president and division head for Cancer Prevention and Population Sciences at The University of Texas M. D. Anderson Cancer Center. 

Prior to his appointment at M. D. Anderson in December 2007, Hawk held several positions at the National Cancer Institute in Bethesda, MD, since 1996. Hawk most recently served as director of the Office of Centers, Training and Resources. His other NCI posts included chief and medical officer in the Gastrointestinal and Other Cancers Research Group, medical officer in the Chemoprevention Branch and chair of the Translational Research Working Group. 

Hawk has been involved in preclinical and clinical chemoprevention research focused on nonsteroidal anti-inflammatory drugs and COX-2 inhibitors, and he has earned numerous awards, including the NCI Research Award for Distinguished Achievement in Cancer Prevention. 

A native of Detroit, MI, Hawk earned his bachelor’s and medical degrees at Wayne State University and his master of public health degree at Johns Hopkins University. He completed an internal medicine internship and residency at Emory University, a medical oncology clinical fellowship at the University of California, San Francisco and a cancer prevention fellowship at NCI. 

Hawk currently serves as deputy editor for Cancer Prevention Research.

For more information or to discuss issues related to any of Hawk’s areas of responsibility, you may contact him by calling 713-792-3900. You may also arrange a meeting through his executive assistant Cheri McClellan, by calling 713-745-0176 or via e-mail to cjmcclel@mdanderson.org

Research Interests

Cancer Prevention

Translational Research

Molecular Intersections between Cancer and Other Diseases

Education & Training

Degree-Granting Education

1994 Johns Hopkins University School Of Hygiene & Pub Health, Baltimore, MD, MPH, Epidemiology/Biostatistics
1985 Wayne State University School of Medicine, Detroit, MI, MD, Medicine
1981 Wayne State University, Detroit, MI, BS, Biological Sciences

Postgraduate Training

1993-1996 Research Fellowship, Cancer Prevention Fellowship, National Cancer Institute, Bethesda, MD, Douglas Weed, MD, MPH, PhD
1991-1993 Clinical Fellowship, Medical Oncology Clinical Fellowship, University Of California, San Francisco, San Francisco, CA, Marc Shuman, MD & I. Craig Henderson, MD
1985-1988 Clinical Internship, Internal Medicine Internship/Residency, Emory University Affiliated Hospitals, Atlanta, GA, J. Willis Hurst, MD & Juha P. Kokko, MD, PhD

Board Certifications

1993 American Board of Internal Medicine - Diplomate in Medical Oncology
1993 American Board of Internal Medicine - Recertification in Medical Oncology
1988 American Board of Internal Medicine - Diplomate in Internal Medicine
1986 National Board of Medical Examiners - Diplomate

Selected Publications

Peer-Reviewed Original Research Articles
1. Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, Leischow S, Grad O, for the Translational Research Working Group. The Translational Research Working Group Development Pathway for Lifestyle Alterations. Clin Cancer Res 14(18):5707-5713, http://clincancerres.aacrjournals.org/cgi/content/abstract/14/18/5707, 9/2008. e-Pub 7/2008.
2. Meyskens, Jr. FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kellorr G, Lawson MJ, Kidao J, McCracken J, Aibers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. Cancer Prev Res 1(1):32-38, 6/2008.
3. Solomon Scott D., Wittes Janet, Finn Peter V., Fowler Robert, Viner Jaye, Bertagnolli Monica M., Arber Nadir, Levin Bernard, Meinert Curtis L., Martin Barbara, Pater Joseph L., Goss Paul E., Lance Peter, Obara Stefanie, Chew Emily Y., Kim Jonghyeon, Arndt Gretchen, Hawk Ernest, for the Cross Trial Safety Assessment Group. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials The Cross Trial Safety Analysis. Circulation, 3/2008.
4. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA. Secondary chemoprevention of Barrett's Esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99:545-557, 2007.
5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K-M, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med for the APC Study Investigators 355:873-884, 2006.
6. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med for the Adenoma Prevention with Celecoxib (APC) Study Investigators 352:1071-1080, 2005.
7. Limburg PJ, Wei W, Ahene DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, Caldwell KL, Dong Z, Taylor PR, Dawsey SM. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 129:863-873, 2005.
8. Lam S, leRiche JC, McWilliams A, MacAulay C, Dyachkova Y, Szabo E, Mayo J, Schellenberg R, Coldman A, Hawk E, Gazdar A. A randomized phase IIb trial of Pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 10:6502-6511, 2004.
9. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004.
10. Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860, 2002.
11. Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, Hawk E, Christen MO, Gazdar AF. A randomized phase IIb trial of anethole dithiolethione (Sialor) in smokers with bronchial dysplasia. J Natl Cancer Inst 94:1001-1009, 2002.
12. Anderson WF, Guyton KZ, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst 94:1126-1133, 2002.
13. Hawk E, Viner JL, Lawrence JA. Biomarkers as surrogates for cancer development. Current Oncol Reports 2:1-9, 2000.
14. Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordon G, Sherman J, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000.

Last updated: 9/24/2009